Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWJ1439/DWJ1464 vs DWC202108/DWC202109 in Healthy Adults
NCT05832697Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ursodeoxycholic acid in primary biliary cholangitis (PBC) and cholelithiasis (4 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration, Maximum Plasma Concentration and 2 more. Started Jan 2022; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)cholelithiasis
Beyond the preview
Go deeper on NCT05832697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832697.